Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer Prevention
Optimal dosing for Indole-3-carbinol investigated
September 22nd, 2005
An optimal dosing for Indole-3-carbinol was recently investigated. Scientists in the United States "completed a phase I trial of indole-3-carbinol (I3C) in 17 women (1 postmenopausal and 16 premenopausal) from a high-risk breast cancer cohort. After a 4-week placebo run-in period, subjects ingested 400 mg I3C daily for 4 weeks followed by a 4-week period of 800 mg I3C daily." "These chronic doses were tolerated well by all subjects," wrote G. A. Reed and colleagues. "Hormonal variables were measured near the end of the placebo and dosing periods, including determination of the urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio. Measurements were...
Source: Women's Health Weekly (2005-09-22)
|
